Chargement en cours...
Recent Advances in the Pharmacology of Tardive Dyskinesia
Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine transporter-2 (VMAT2) inhibitors offers hope for reducing the impact of TD. Although these drugs represent a significant advanc...
Enregistré dans:
| Publié dans: | Clin Psychopharmacol Neurosci |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Korean College of Neuropsychopharmacology
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7609206/ https://ncbi.nlm.nih.gov/pubmed/33124584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9758/cpn.2020.18.4.493 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|